Drugs / Bevifibatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06712004 | Feb → Sep 2025 overdue | cerebral infarction | Zhujiang Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevifibatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06712004 ↗ |
| Known as | Bevifibatide citrate injection | “Bevifibatide citrate injection should be diluted with 0.9% NaCl solution.” NCT06712004 ↗ |
| Action | Inhibit | “It also inhibits the integrin receptor αvβ3” NCT06712004 ↗ |
| Route | Intravenous | “its clinical formulation is an injectable solution for intravenous administration.” NCT06712004 ↗ |